The primary use of trazodone is the treatment of major depression. Data from open and double-blind trials suggest the antidepressant efficacy of trazodone is comparable to that of amitriptyline, doxepin, and mianserin. Also, trazodone showed anxiolytic properties, low cardiotoxicity, and relatively mild side effects. Because trazodone has minimal anticholinergic activity, it was especially welcomed as a treatment for geriatric patients with depression when it first became available. Three double-blind studies reported trazodone has antidepressant efficacy similar to that of other antidepressants in geriatric patients. However, a side effect of trazodone, orthostatic hypotension, which may cause dizziness and increase the risk of falling, can have devastating consequences for elderly patients; thus, this side effect, along with sedation, often makes trazodone less acceptable for this population, compared with newer compounds that share its lack of anticholinergic activity but not the rest of its side-effect profile. Still, trazodone is often helpful for geriatric patients with depression who have severe agitation and insomnia. Trazodone has also been reported to have antianxiety properties. In a randomized, double-blind, placebo-controlled trial, the anxiolytic efficacy of trazodone was comparable to that of diazepam in weeks 3–8 of treatment for generalized anxiety disorder, although patients treated with diazepam had greater improvement during the first 2 weeks of treatment. Early case reports had indicated that trazodone is associated with improvement in obsessive-compulsive disorder, but a double-blind, placebo-controlled study found that trazodone lacked antiobsessional effects. Many clinicians use low-dose trazodone as an alternative to benzodiazepines for the treatment of insomnia. Two recent reviews found that trazodone is the second most prescribed agent for insomnia, though few data support trazodone's use in primary insomnia, because most studies have been limited to patients with depression.
Because of its lack of anticholinergic side effects, trazodone is especially useful in situations in which antimuscarinic effects are particularly problematic (e.g., in patients with prostatic hypertrophy, closed-angle glaucoma, or severe constipation). Trazodone's propensity to cause sedation is a dual-edged sword. For many patients, the relief from agitation, anxiety, and insomnia can be rapid; for other patients, including those individuals with considerable psychomotor retardation and feelings of low energy, therapeutic doses of trazodone may not be tolerable because of sedation. Trazodone elicits orthostatic hypotension in some patients, probably as a consequence of 1-adrenergic receptor blockade. Mania has been observed in association with trazodone treatment (as with nearly all antidepressants), including in patients with bipolar disorder, as well as in patients with previous diagnoses of unipolar depression. Compared to the reversible MAOI antidepressant drug moclobemide, significantly more impairment of vigilance occurs with trazodone.
Case reports have noted cardiac arrhythmias emerging in relation to trazodone treatment, both in patients with pre-existing mitral valve prolapse and in patients with negative personal and family histories of cardiac disease.
QT prolongation has been reported with trazodone therapy. Arrhythmia identified include isolated PVCs, ventricular couplets, and in two patients short episodes (three to four beats) of ventricular tachycardia. Several post-marketing reports have been made of arrhythmia in trazodone-treated patients who have pre-existing cardiac disease and in some patients who did not have pre-existing cardiac disease. Until the results of prospective studies are available, patients with pre-existing cardiac disease should be closely monitored, particularly for cardiac arrhythmias. Trazodone is not recommended for use during the initial recovery phase of myocardial infarction. Concomitant administration of drugs that prolong the QT interval or that are inhibitors of CYP3A4 may increase the risk of cardiac arrhythmia.
A relatively rare, but dramatic, side effect associated with trazodone is priapism, likely due to its antagonism at α-adrenergic receptors. Priapism is a potentially harmful medical condition in which the erect penis does not return to its flaccid state (despite the absence of both physical and psychological stimulation) within four hours. More than 200 cases have been reported, and the manufacturer estimated the incidence of any abnormal erectile function is about one in 6,000 male patients treated with trazodone. The risk for this side effect appears to be greatest during the first month of treatment at low dosages (i.e. <150 mg/day). Early recognition of any abnormal erectile function, including prolonged or inappropriate erections, is important and should prompt discontinuation of trazodone treatment. Clinical reports have also described trazodone-associated psychosexual side effects in women, including increased libido, priapism of the clitoris, and spontaneous orgasms.
Rare cases of idiosyncratic hepatotoxicity have been observed, possibly due to the formation of reactive metabolites.
Elevated prolactin concentrations have been observed in patients taking trazodone.
If the patient is under 18 years of age and combined with other antidepressant medications, it may increase the possibility of suicidal thoughts or actions.
Trazodone is metabolized by CYP3A4, a liver enzyme. Inhibition of this enzyme by various other substances may delay its degradation, leading to high blood levels of trazodone. CYP3A4 may be inhibited by many other medications, herbs, and foods, and as such, trazodone may interact with these substances. One drug-food interaction is grapefruit juice. Drinking grapefruit juice is discouraged in patients taking trazodone. One glass of grapefruit juice occasionally is not likely to have this effect on most people, but drinking large amounts, or drinking it regularly is proven to affect trazodone's clearance.
The possibility of suicide in depressed patients remains during treatment and until significant remission occurs. The number of tablets prescribed at any one time should take into account this possibility, and patients with suicidal ideation should never have access to large quantities of trazodone.
Trazodone has been reported to cause seizures in a small number of patients who took it concurrently with medications to control seizures.
While trazodone is not a true member of the SSRI class of antidepressants, it does still share many properties of the SSRIs, especially the possibility of discontinuation syndrome if the medication is stopped too quickly. Care must, therefore, be taken when coming off the medication, usually by a gradual process of tapering down the dose over a period of time.
Pregnancy and lactation
Sufficient data in humans are lacking. Use should be justified by the severity of the condition to be treated.
Since trazodone may impair the mental and/or physical abilities required for performance of potentially hazardous tasks, such as operating an automobile or machinery, the patient should be cautioned not to engage in such activities while impaired.
Trazodone appears to be relatively safer than TCAs, MAOIs, and a few of the other second-generation antidepressants in overdose situations, especially when it is the only agent taken. Fatalities are rare, and uneventful recoveries have been reported after ingestion of doses as high as 6,000–9,200 mg. In one report, 9 of 294 cases of overdose were fatal, and all 9 patients had also taken other central nervous system (CNS) depressants. When trazodone overdoses occur, clinicians should carefully monitor for hypotension, a potentially serious toxic effect. In a report of a fatal trazodone overdose, torsades de pointes and complete atrioventricular block developed, along with subsequent multiple organ failure, with a trazodone plasma concentration of 25.4 g/mL Template:Mg/L?? on admission.
There is no specific antidote for trazodone. Management of overdosage should, therefore, be symptomatic and supportive. Any person suspected of having taken an overdosage should be evaluated at a hospital as soon as possible. Activated charcoal, gastric lavage, and forced diuresis may be useful in facilitating elimination of the drug.
Trazodone may enhance the effects of alcohol, barbiturates, and other CNS depressants; patients should be cautioned accordingly, as trazodone with the combination of another CNS depressant, can result in extreme tiredness and dizziness.
Increased serum digoxin and phenytoin levels have been reported to occur in patients receiving trazodone concurrently with either of those two drugs. Little is known about the interaction between trazodone and general anesthetics; therefore, prior to elective surgery, trazodone should be discontinued for as long as clinically feasible.
Because it is not known whether an interaction will occur between trazodone and monoamine oxidase inhibitors (MAOIs), administration of trazodone should be initiated very cautiously with gradual increase in dosage as required, if an MAOI is given concomitantly or has been discontinued shortly before medication with trazodone is instituted.
Legend: ND - No data GPC - Cloned guinea pig receptor. P - Peripheral receptor C - Central receptor RC - Cloned rat receptor RK - Rat kidney receptor HB - Human brain receptor RPC12 - Rat PC12 receptor Bold text indicates that binding affinities for cloned human receptors is unavailable.
Correspondence to clinical effects
Trazodone acts predominantly as a 5-HT2A receptor antagonist to mediate its therapeutic benefits against anxiety and depression. Its inhibitory effects on serotonin reuptake and 5-HT2C receptors are relatively weak (~15-fold lower than for 5-HT2A) and contribute only lightly to its overall effects. Hence, trazodone does not have similar properties to selective serotonin reuptake inhibitors (SSRIs) and is not particularly associated with increased appetite and weight gain, unlike other 5-HT2C antagonists like mirtazapine. Moderate 5-HT1A partial agonism (6-fold lower than 5-HT2A) is likely to contribute to trazodone's antidepressant and anxiolytic actions to some extent as well.
The combined actions of 5HT2A/5HT2C antagonism with SERT inhibition only occur at moderate to high doses of trazodone. Doses of trazodone lower than those effective for antidepressant action are frequently used for the effective treatment of insomnia. Low doses exploit trazodone’s potent actions as a 5HT2A antagonist, and its properties as an antagonist of H1-histaminic and α1-adrenergic receptors, but do not adequately exploit its SERT or 5HT2C inhibition properties, which are weaker. Since insomnia is one of the most frequent residual symptoms of depression after treatment with an SSRI, a hypnotic is often necessary for patients with a major depressive episode. Not only can a hypnotic potentially relieve the insomnia itself, but treating insomnia in patients with major depression may also increase remission rates due to improvement of other symptoms such as loss of energy and depressed mood. Thus, the ability of low doses of trazodone to improve sleep in depressed patients may be an important mechanism whereby trazodone can augment the efficacy of other antidepressants.
Trazodone's potent α1-adrenergic blockade (about threefold lower relative to 5-HT2A) may cause some side effects like orthostatic hypotension and sedation. Conversely, along with 5-HT2A antagonism, it may underlie its efficacy as a hypnotic. This seems possible as trazodone's antihistamine activity is relatively weak and probably clinically insignificant; hence, it cannot explain trazodone's sleep-inducing/enhancing effects. Trazodone lacks any affinity for the mACh receptors, so does not produce anticholinergic side effects.
mCPP, a nonselectiveserotonin receptor agonist and serotonin releasing agent, is an active metabolite of trazodone and has been suggested to possibly play a role in its therapeutic benefits. However, scientific research has not supported this hypothesis, and mCPP may actually antagonize trazodone's efficacy as well as produce additional side effects. mCPP is also a metabolite of aripiprazole. Aripiprazole's primary serotonergic effect is at the 5-HT2B receptor where it functions as an antagonist with a Ki of 0.36 nM. Trazodone antagonizes the 5-HT2B (Ki = 78.4 nM) stronger than any serotonergic receptor except for 5-HT2A (Ki = 8.7 nM). Also, there are six 5-HT receptors that trazodone and aripiprazole both effect, but their strength varies in order. Aripiprazole's order of strength is as follows: 5-HT2B receptor, 5-HT1A receptor, 5-HT7 receptor, 5-HT2A receptor, 5-HT2C receptor, 5-HT1D receptor. Trazodone's order of strength is as follows: 5-HT2A receptor, 5-HT2B receptor, 5-HT1D receptor, 5-HT1A receptor, 5-HT2C receptor, 5-HT7 receptor. Trazodone has strong similarities to the atypical antipsychotic, aripiprazole, and both psychiatric medications produce the mCPP metabolite.
Trazodone is well absorbed after oral administration, with mean peak blood levels obtained at about one hour after ingestion. Absorption is somewhat delayed and enhanced by food. The mean blood elimination half-life is biphasic: the first phase's half-life is 3–6 hr, and the following phase's half-life is 5–9 hr. The drug is extensively metabolized, with three or four major metabolites having been identified in the human body, particularly mCPP, which may contribute to the side effect profile of trazodone. mCPP has been shown to activate numerous serotonin receptors, including 5-HT2C. Around 70–75% of 14C-labelled trazodone was found to be excreted in the urine within 72 hours. Trazodone is highly protein-bound.
As a consequence of the production of mCPP as a metabolite, patients administered trazodone may test positive on EMIT II urine tests for the presence of MDMA ("ecstasy").
White blood cell and differential counts should be performed in patients who develop sore throat, fever, or other signs of infection or blood dyscrasia, and trazodone should be discontinued if the white blood cell or absolute neutrophil counts fall below normal.
Forms of trazodone
Trazodone tablets are available in 50-, 100-,150 and 300-mg strengths. The active ingredient is trazodone hydrochloride, USP.
Inactive ingredients vary by manufacturer. See manufacturer package insert for more information.
Trazodone was originally discovered and developed in Italy in the 1960s by Angelini Research Laboratories as a second-generation antidepressant. It was developed according to the mental pain hypothesis, which was postulated from studying patients and which proposes that major depression is associated with a decreased pain threshold. In sharp contrast to most other antidepressants available at the time of its development, trazodone showed minimal effects on muscarinic cholinergic receptors. Trazodone was patented and marketed in many countries all over the world. It was approved by the Food and Drug Administration (FDA) at the end of 1981.
^ abcdTruven Health Analytics, Inc. DrugPoint® System (Internet) [cited 2013 Oct 1]. Greenwood Village, CO: Thomsen Healthcare; 2013.
^Haria M, Fitton A, McTavish D (April 1994). "Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders". Drugs Aging4 (4): 331–55. doi:10.2165/00002512-199404040-00006. PMID8019056.
^ abcdeSchatzberg, AF; Nemeroff, CB, eds. (2009). Textbook of Psychopharmacology (4th ed.). Washington D.C.: American Psychiatric Publishing. ISBN978-1-58562-309-9.
^British National Formulary (BNF) 65. London, UK: Pharmaceutical Press. 2013. p. 247. ISBN9780857110848.
^Warner,, M. D.,; Dorn,, M. R.,; Peabody, C. A., (2001). "Survey on the Usefulness of Trazodone in Patients with PTSD with Insomnia or Nightmares". Pharmacopsychiatry34 (4): 128–131. doi:10.1055/s-2001-15871. PMID11518472
^ abRickels K, Downing R, Schweizer E, Hassman H (November 1993). "Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam". Arch. Gen. Psychiatry50 (11): 884–95. doi:10.1001/archpsyc.1993.01820230054005. PMID8215814.
^ abPigott TA, L'Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL (June 1992). "A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder". J Clin Psychopharmacol12 (3): 156–62. doi:10.1097/00004714-199202000-00003. PMID1629380.
^Roccatagliata G; Albano C, Maffini M, Farelli S (1980). "Alcohol withdrawal syndrome: treatment with trazodone". Int Pharmacopsychiatry.15 (2): 105–10. PMID6108298.Cite uses deprecated parameters (help)
^Le Bon O; Murphy JR, Staner L, Hoffmann G, Kormoss N, Kentos M, Dupont P, Lion K, Pelc I, Verbanck P (August 2003). "Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations". J Clin Psychopharmacol23 (4): 377–83. doi:10.1097/01.jcp.0000085411.08426.d3. PMID12920414.Cite uses deprecated parameters (help)
^Borras L; de Timary P, Constant EL, Huguelet P, Eytan A (November 2006). "Successful treatment of alcohol withdrawal with trazodone". Pharmacopsychiatry39 (6): 232. doi:10.1055/s-2006-951385. PMID17124647.Cite uses deprecated parameters (help)
^Einarson, A; Bonari, L; Voyer-Lavigne, S; Addis, A; Matsui, D; Johnson, Y; Koren, G (March 2003). "A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy". Can J Psychiatry48 (2): 106–110. PMID12655908.
^Verbeeck, RK; Ross, SG; McKenna, EA (September 1986). "Excretion of trazodone in breast milk". Br J Clin Pharmacol22 (3): 367–370. PMID3768252.
^de Meester A, Carbutti G, Gabriel L, Jacques JM (2001). "Fatal overdose with trazodone: case report and literature review". Acta Clin Belg56 (4): 258–61. PMID11603256.
^Rakel RE (1987). "The greater safety of trazodone over tricyclic antidepressant agents: 5-year experience in the United States". Psychopathology20 (Suppl 1): 57–63. doi:10.1159/000284524. PMID3321131.
^Wander TJ, Nelson A, Okazaki H, Richelson E (December 1986). "Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro". European Journal of Pharmacology132 (2–3): 115–21. doi:10.1016/0014-2999(86)90596-0. PMID3816971.
^Cusack B, Nelson A, Richelson E (May 1994). "Binding of antidepressants to human brain receptors: focus on newer generation compounds". Psychopharmacology114 (4): 559–65. doi:10.1007/BF02244985. PMID7855217.
^ abRaffa RB, Shank RP, Vaught JL (1992). "Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity". Psychopharmacology108 (3): 320–6. doi:10.1007/BF02245118. PMID1387963.
^Roth, BL; Driscol, J (2011-01-12). "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health.
^ abcMarek GJ, McDougle CJ, Price LH, Seiden LS (1992). "A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action". Psychopharmacology109 (1–2): 2–11. doi:10.1007/BF02245475. PMID1365657.
^Asayesh K (December 1986). "Combination of trazodone and phenothiazines: a possible additive hypotensive effect". Canadian Journal of Psychiatry31 (9): 857–8. PMID3802006.
^Melzacka M, Rurak A, Vetulani J (1980). "Preliminary study of the biotransformation of two new drugs, trazodone and etoperidone". Polish Journal of Pharmacology and Pharmacy32 (4): 551–6. PMID7255270.
^Fong MH, Garattini S, Caccia S (October 1982). "1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole". The Journal of Pharmacy and Pharmacology34 (10): 674–5. doi:10.1111/j.2042-7158.1982.tb04701.x. PMID6128394.
^Li AA, Marek GJ, Hand TH, Seiden LS (February 1990). "Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite m-chlorophenylpiperazine". European Journal of Pharmacology177 (3): 137–44. doi:10.1016/0014-2999(90)90263-6. PMID2311675.
^Vetulani J, Sansone M, Baran L, Hano J (1984). "Opposite action of m-chlorophenylpiperazine on avoidance depression induced by trazodone and pimozide in CD-1 mice". Psychopharmacology83 (2): 166–8. doi:10.1007/BF00429728. PMID6431467.
^Workman EA, Tellian F, Short D (May 1992). "Trazodone induction of migraine headache through mCPP". The American Journal of Psychiatry149 (5): 712. PMID1575270.
^Jauch R, Kopitar Z, Prox A, Zimmer A (1976). "[Pharmacokinetics and metabolism of trazodone in man (author's transl)]" [Pharmacokinetics and metabolism of trazodone in man (author's transl)]. Arzneimittelforschung (in German) 26 (11): 2084–9. PMID1037253.
^Logan BK, Costantino AG, Rieders EF, Sanders D (Nov 2010). "Trazodone, meta-chlorophenylpiperazine (an hallucinogenic drug and trazodone metabolite), and the hallucinogen trifluoromethylphenylpiperazine cross-react with the EMIT®II ecstasy immunoassay in urine". J Anal Toxicol34 (9): 587–9. PMID21073812.